Want to see HK:2158 full AI Analyst Report?
2158 Stock Chart & Stats
HK$5.58
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$5.58
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$4.05 - HK$7.24
Previous CloseN/A
Volume5.15M
Average Volume (3M)6.50M
Market Cap
HK$5.56B
Enterprise ValueHK$3.60B
Total Cash (Recent Filing)HK$2.22B
Total Debt (Recent Filing)HK$76.78M
Price to Earnings (P/E)64.8
Beta1.75
Next Earnings
Nov 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding1,072,818,200
10 Day Avg. Volume6,345,530
30 Day Avg. Volume6,499,248
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)1.25
Price to Sales (P/S)5.73
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$6.80Price Target Upside21.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.05
Revenue Forecast (FY)HK$972.31M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage provides durable financial flexibility to support R&D and absorb industry cyclicality. A strong equity base (~83.6%) gives optionality for strategic investments, partnerships, or M&A without incurring heavy interest burdens while management works to restore profitability.
Improving Free Cash FlowRising free cash flow growth and a positive FCF-to-net-income ratio indicate improving cash conversion despite accounting losses. Sustained FCF improvements reduce dependence on dilutive financing, support continued investment in product and data infrastructure, and extend the company’s operational runway.
Strategic AI Healthcare FocusThe core business of converting real-world clinical data into structured datasets addresses structural healthcare trends—digitization, real-world evidence needs, and AI adoption. Focus on hospitals and pharma targets recurring, high-value use cases that can create sticky customer relationships and network effects over time.
Bears Say
Declining Revenue GrowthSustained revenue decline reduces scale advantages and limits the company’s ability to invest in product development, sales, and data acquisition. If top-line contraction continues, margin recovery and the path to profitability become harder, increasing financing needs and strategic execution risk.
Negative Profitability And ROEPersistent negative margins and a negative ROE indicate the business currently destroys shareholder value and lacks internal earnings to fund growth. Long-term viability requires a credible plan to restore operating margins; otherwise the firm will remain reliant on external capital, constraining strategic flexibility.
Negative Operating Cash FlowNegative operating cash flow signals the core operations are not converting revenue into cash, creating ongoing funding needs. Even with improved FCF metrics, persistent OCF deficits pressure liquidity, force reliance on financing or reserves, and limit the company’s ability to reinvest in growth sustainably.
Yidu Tech, Inc. News
2158 FAQ
What was Yidu Tech, Inc.’s price range in the past 12 months?
Yidu Tech, Inc. lowest stock price was HK$4.05 and its highest was HK$7.24 in the past 12 months.
What is Yidu Tech, Inc.’s market cap?
Yidu Tech, Inc.’s market cap is HK$5.56B.
When is Yidu Tech, Inc.’s upcoming earnings report date?
Yidu Tech, Inc.’s upcoming earnings report date is Nov 20, 2026 which is in 125 days.
How were Yidu Tech, Inc.’s earnings last quarter?
Yidu Tech, Inc. released its earnings results on Jun 30, 2026. The company reported HK$0.092 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.092.
Is Yidu Tech, Inc. overvalued?
According to Wall Street analysts Yidu Tech, Inc.’s price is currently Undervalued.
Does Yidu Tech, Inc. pay dividends?
Yidu Tech, Inc. pays a N/A dividend of HK$0.04 which represents an annual dividend yield of N/A. See more information on Yidu Tech, Inc. dividends here
What is Yidu Tech, Inc.’s EPS estimate?
Yidu Tech, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Yidu Tech, Inc. have?
Yidu Tech, Inc. has 1,072,818,200 shares outstanding.
What happened to Yidu Tech, Inc.’s price movement after its last earnings report?
Yidu Tech, Inc. reported an EPS of HK$0.092 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 6.422%.
Which hedge fund is a major shareholder of Yidu Tech, Inc.?
Currently, no hedge funds are holding shares in HK:2158
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Yidu Tech, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.55%
12-Months-Change
Fundamentals
Return on Equity
-2.28%
Trailing 12-Months
Asset Growth
-2.66%
Trailing 12-Months
Company Description
Yidu Tech, Inc.
Yidu Tech Inc. is a technology company that develops and deploys healthcare solutions leveraging big data and artificial intelligence. Its operations extend across Mainland China, Brunei, and other global regions. The company's business activities are categorized into four core segments: Big Data Platform and Solutions, Life Sciences Solutions, Health Management Platform and Solutions, and a segment for Other ventures. The Big Data Platform and Solutions division provides sophisticated data intelligence platforms and analytics-driven solutions. These offerings cater to hospitals, diverse healthcare institutions, regulatory bodies, and policymakers, aiming to enhance research, clinical diagnosis and treatment, and operational efficiency. This segment specifically includes the provision of DPAP/Eywa platforms for medical organizations. Through its Life Sciences Solutions segment, the company delivers analytical services that support clinical development, real-world evidence (RWE) research, and digital commercialization strategies for pharmaceutical companies, biotechnology firms, and medical device manufacturers. The Health Management Platform and Solutions segment offers health management applications and services, as well as insurance technology (InsurTech) solutions for insurance companies, agencies, and relevant regulators. This segment also includes the distribution of insurance products and the sale of pharmaceuticals and associated hardware. The Others segment encompasses the sale of computer hardware, medical devices, insurance brokerage services, and engagement in medical and computer technology development. Yidu Tech Inc. was established in 2014 and is headquartered in Beijing, China.
2158 Stock 12 Month Forecast
Average Price Target
HK$6.80
▲(21.86% Upside)
Technical Analysis
Ping An Healthcare and Technology Company
―
Kindstar Globalgene Technology, Inc.
―
Medlive Technology Co., Ltd.
―
NEUSOFT XIKANG HOLDINGS INC.
―
Xunfei Healthcare Technology Co., Ltd.
―